Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLAFEM 0.5/35 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits gonadotropin release, suppressing ovulation. Increases cervical mucus viscosity and alters endometrium, reducing sperm penetration and implantation.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years,Oral contraceptive
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (0.5 mg norethindrone/35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days (or no tablets) per cycle.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Terminal elimination half-life of norethindrone is 5-14 hours (mean 7.6 hours); ethinyl estradiol half-life is 7-20 hours (mean ~13 hours). Steady-state is achieved within 5-7 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Norethindrone undergoes hepatic metabolism via reduction and hydroxylation followed by glucuronidation; ethinyl estradiol is metabolized primarily by CYP3A4 and undergoes first-pass metabolism with sulfation and glucuronidation in the gut wall and liver.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal excretion accounts for approximately 50-60% of the dose (as metabolites), with 30-40% excreted in feces via biliary elimination. Unchanged drug is minimal in urine.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norethindrone: ~97% bound to albumin and SHBG. Ethinyl estradiol: ~98% bound to albumin.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norethindrone: Vd ~4 L/kg (total body water and tissue distribution). Ethinyl estradiol: Vd ~2.5 L/kg.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral bioavailability: norethindrone ~64% (due to first-pass metabolism); ethinyl estradiol ~45% (range 38-55%).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No specific dosage adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential adverse effects on renal function and hormonal balance.
No data available for fictional drug ALYACEN 777.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). For mild hepatic impairment (Child-Pugh class A), use with caution; no specific dose adjustment but monitor liver function tests.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily per cycle) following standard contraceptive guidelines for adolescents.
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenopausal women due to lack of contraceptive need and increased risk of cardiovascular events and thromboembolism with estrogen-containing contraceptives.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and with heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Ocular changes (retinal thrombosis),Depression,Headache/migraine,Hereditary angioedema exacerbation,Chloasma,Hepatic impairment,Pregnancy discontinuation,Lactation use
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-sensitive neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Age >35 and smoking ≥15 cigarettes/day
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food restrictions. Grapefruit juice may slightly increase estrogen levels but not clinically significant. Maintain a balanced diet for overall health.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
FIRST TRIMESTER: Increased risk of neural tube defects, cardiovascular malformations, and orofacial clefts with inadvertent exposure; absolute risk estimated at 3-4% above baseline. SECOND TRIMESTER: No direct teratogenic risk, but continue to avoid use due to hormonal effects. THIRD TRIMESTER: Potential for adverse fetal outcomes including respiratory distress, neonatal jaundice, and hypoglycemia; use contraindicated throughout pregnancy.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Contraindicated in breastfeeding. Estrogen and progestin are excreted in breast milk; M/P ratio unknown. May reduce milk production and alter milk composition. Theoretical risk of adverse effects in nursing infant. Alternative contraception recommended.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Not applicable; drug is contraindicated in pregnancy. No dose adjustment recommended as use should be discontinued immediately upon confirmed pregnancy.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
CYCLAFEM 0.5/35 (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) is a monophasic combination oral contraceptive. The 0.5 mg norethindrone dose is lower than typical progestin doses, reducing androgenic side effects. Its lower estrogen content (35 mcg) still provides effective cycle control. It is a first-line option for patients desiring contraception with minimal hormonal exposure. Breakthrough bleeding may occur in the first few cycles, especially with missed pills. Contraindicated in patients with migraine with aura, thrombophilia, or history of estrogen-dependent neoplasia.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill, refer to the package insert instructions; use backup contraception if needed.,Side effects may include nausea, breast tenderness, or spotting, especially during the first few months.,Smoking increases risk of serious cardiovascular events while on this medication; avoid smoking.,This medication does not protect against sexually transmitted infections (STIs); use condoms for STI prevention.,Notify your healthcare provider before starting new medications, as some (e.g., rifampin, certain anticonvulsants) may reduce effectiveness.,Store at room temperature, away from moisture and heat.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLAFEM 0.5/35 vs ALYACEN 777, answered by our medical review team.
CYCLAFEM 0.5/35 is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits gonadotropin release, suppressing ovulation. Increases cervical mucus viscosity and alters endometrium, reducing sperm penetration and implantation.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLAFEM 0.5/35 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLAFEM 0.5/35 is: One tablet (0.5 mg norethindrone/35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days (or no tablets) per cycle.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLAFEM 0.5/35 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLAFEM 0.5/35 is classified as Category C. FIRST TRIMESTER: Increased risk of neural tube defects, cardiovascular malformations, and orofacial clefts with inadvertent exposure; absolute risk estimated at 3-4% above baseline. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.